International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
2016 · The Lancet Oncology · 2,843 citations
https://doi.org/10.1016/s1470-2045(16)30206-6
P
Philippe Moreau
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2.3K
Papers
107.7K
Citations
159
h-index
953
i10-index
Philippe Moreau is an academic researcher from Centre National de la Recherche Scientifique. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 159, co-authored 1940 publications.
ORCID: 0000-0003-1780-8746Papers by this author
worksIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
2021 · New England Journal of Medicine · 2,258 citations
https://doi.org/10.1056/nejmoa2024850
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
2005 · American Journal of Hematology · 1,401 citations
https://doi.org/10.1002/ajh.20381
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2016 · New England Journal of Medicine · 1,037 citations
https://doi.org/10.1056/nejmoa1516282
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
2014 · Nature Communications · 890 citations
https://doi.org/10.1038/ncomms3997
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
2017 · The Lancet Oncology · 502 citations
https://doi.org/10.1016/s1470-2045(17)30189-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat